Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Announces Approval and Launch Of First Generic Rectiv®
Details : Rectiv-Generic (nitroglycerin) is a nitrate vasodilator activating guanylate cyclase to increase cyclic GMP in smooth muscle. It is indicated for treating moderate to severe chronic anal fissure pain.
Product Name : Rectiv-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MED2005,Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating MED2005 & Nitrostat Bioavailability
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 05, 2019
Lead Product(s) : MED2005,Nitroglycerin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Evolocumab,Iohexol,Metoprolol Tartrate,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Evolocumab on Coronary Atherosclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
October 01, 2018
Lead Product(s) : Evolocumab,Iohexol,Metoprolol Tartrate,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BMS-986231,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2017
Lead Product(s) : BMS-986231,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Details : Undisclosed
Product Name : Vascana
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2016
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vericiguat,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 01, 2015
Lead Product(s) : Vericiguat,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin,Citric Acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2015
Lead Product(s) : Nitroglycerin,Citric Acid,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 16, 2015
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Health Research Board, Ireland
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2015
Lead Product(s) : Nitroglycerin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guanxin Shutong,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
November 02, 2014
Lead Product(s) : Guanxin Shutong,Nitroglycerin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable